Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CNSX:ATTTSE:ICP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATTAbattis BioceuticalsC$0.00C$0.05▼C$0.74N/AN/A1.42 million shsN/AICPBelgravia Capital International Inc,C$0.00C$0.02▼C$0.12C$14.59MN/A698,779 shs8.14 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATTAbattis Bioceuticals0.00%0.00%0.00%0.00%0.00%ICPBelgravia Capital International Inc,0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATTAbattis BioceuticalsN/AN/AN/AN/AN/AN/AN/AN/AICPBelgravia Capital International Inc,N/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATTAbattis Bioceuticals 0.00N/AN/AN/AICPBelgravia Capital International Inc, 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATTAbattis BioceuticalsN/AN/AN/AN/AN/AN/AICPBelgravia Capital International Inc,N/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATTAbattis BioceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/AICPBelgravia Capital International Inc,N/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATTAbattis BioceuticalsN/AN/AN/AN/AN/AICPBelgravia Capital International Inc,N/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATTAbattis BioceuticalsN/AICPBelgravia Capital International Inc,N/AInsider OwnershipCompanyInsider OwnershipATTAbattis BioceuticalsN/AICPBelgravia Capital International Inc,N/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATTAbattis BioceuticalsN/AN/AN/ANot OptionableICPBelgravia Capital International Inc,147,000243.24 millionN/ANot OptionableATT, ICP, SDRC, and MNG HeadlinesRecent News About These CompaniesBelgravia mansion sells for £38 million in London's first super-prime deal of 2025January 9, 2025 | msn.comBlackRock International V.I. Fund Q3 2024 CommentaryNovember 13, 2024 | seekingalpha.comBellevue Capital Partners acquires additional 100,000 shares of Global Net LeaseNovember 13, 2024 | markets.businessinsider.comInternet Computer price prediction 2024-2030: Is ICP a good investment?November 6, 2024 | msn.comLincoln International boosts European presence in preparation for private-equity comebackNovember 4, 2024 | chicagobusiness.comBuca Di Beppo Creditors Challenge Sale to Main Street CapitalOctober 29, 2024 | news.bloomberglaw.comPhiladelphia Board axes Capital Group from international equity portfolioOctober 28, 2024 | pionline.comConavi Medical Corp. Engages ICP Securities Inc. for Automated Market Making ServicesOctober 23, 2024 | markets.businessinsider.comImplenia AG (IPLNF) Receives a Buy from Kepler CapitalSeptember 25, 2024 | markets.businessinsider.comEpica International, Inc. Secures $18 Million Growth Capital Credit Facility From Avenue Capital Group to Drive Innovation and ExpansionSeptember 18, 2024 | markets.businessinsider.comSverica Capital Management invests in boutique aggregator Four IncSeptember 17, 2024 | pehub.comBalchug Capital Welcomes Top Ethics Expert to its New Global Advisory BoardSeptember 17, 2024 | markets.businessinsider.comKepler Capital Reaffirms Their Buy Rating on Implenia AG (IPLNF)September 1, 2024 | markets.businessinsider.comBelgravia Hartford Capital Inc. Provides Corporate UpdateAugust 15, 2024 | msn.comBelgravia Hartford Capital Inc: Belgravia Hartford Closes Second Tranche of Private PlacementAugust 9, 2024 | finanznachrichten.deThe Critical Need for Decentralization: Leveraging ICP Utopia to Mitigate Cybersecurity RisksJuly 22, 2024 | tmcnet.comDFINITY Foundation Unveils New and Updated Roadmap for Internet Computer (ICP)May 17, 2024 | coinspeaker.comINC & CO INVESTMENT GROUP EXPANDS FURTHER INTO RETAIL – ACQUIRES ETHICAL LUXURY LINGERIE COMPANY STUDIO PIAMay 7, 2024 | markets.businessinsider.comICP ReportsMay 3, 2024 | worldbank.orgCACI International: Quality Business Model Evolution But More Progress RequiredApril 2, 2024 | seekingalpha.comTop HeadlinesView All HeadlinesAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in Value3 High-Paying Dividend Stocks That Still Have Safe PayoutsBy Chris Markoch | May 27, 2025View 3 High-Paying Dividend Stocks That Still Have Safe PayoutsThese 3 Stocks Could Be Back in Play Before You Know ItBy Gabriel Osorio-Mazilli | June 10, 2025View These 3 Stocks Could Be Back in Play Before You Know ItNextracker’s Solar Surge: Will It Shatter Its All-Time High?By Thomas Hughes | May 18, 2025View Nextracker’s Solar Surge: Will It Shatter Its All-Time High?Hormel Stock Near Lows, But Tariff Relief Could Boost OutlookBy Chris Markoch | May 29, 2025View Hormel Stock Near Lows, But Tariff Relief Could Boost OutlookATT, ICP, SDRC, and MNG Company DescriptionsAbattis Bioceuticals CNSX:ATTAbattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.Belgravia Capital International Inc, TSE:ICPBelgravia Capital International Inc, formerly known as IC Potash Corp, is a Canada-based company focused on the provision of value-added services to the international Cannabis industry. The Company's activities include the production of specialized organic fertilizers for Cannabis plants, as well as research and development in the area of agronomics through its wholly owned subsidiary, ICP Organics Corp. Additionally, the Company is engaged in the development of blockchain technology software to support the cultivation and distribution processes, such as seed to sale tracking and quality attestation of intermediate and consumer products. The Company is also developing a royalty-streaming subsidiary. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? 3 Stocks With Rising Dividends Investors Shouldn’t Ignore SoundHound’s AI Growth Story Is Just Getting Started MarketBeat Week in Review – 06/09 - 06/13 2 Reasons Adobe Stock Is Ready to Rally This Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
